SMAD7 and myocardial infarction: In cardiac tissues, SMAD7 has shown antifibrotic and cardioprotective effects in models of myocardial infarction (Yuan et al, 2017; Su et al, 2024), hypertrophic obstructive cardiomyopathy (Zhang et al, 2023), heart failure (Humeres et al, 2024), and diabetic cardiomyopathy (Meng et al, 2019; Li et al, 2020).